8-K: Vivos Therapeutics Sets Date and Deadlines for 2024 Annual Meeting

Vivos Therapeutics has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.

Summary

• Vivos Therapeutics plans to hold its 2024 Annual Meeting of Stockholders on Tuesday, November 26, 2024.
• The record date for determining stockholders eligible to vote at the meeting is set for the close of business on Friday, October 4, 2024.
• The deadline for submitting shareholder proposals for inclusion in the proxy statement is September 27, 2024.
• The deadline for submitting director nominations or other proposals to be presented at the meeting is also September 27, 2024.
• All proposals must be sent to the Corporate Secretary at the company's Littleton, Colorado address.

Sentiment

Score: 7

Explanation: The document is a routine announcement of meeting dates and deadlines, which is neutral to slightly positive as it provides clarity to shareholders.

Positives

• The company has provided clear deadlines for shareholder proposals and director nominations, ensuring transparency and allowing shareholders sufficient time to prepare.

Risks

• Failure to meet the deadlines for submitting proposals or nominations will result in exclusion from the proxy materials or the meeting agenda.

Future Outlook

The company will file a definitive proxy statement with the SEC containing the time and location of the 2024 Annual Meeting.

Industry Context

This announcement is a standard procedure for publicly traded companies to organize their annual shareholder meetings and ensure compliance with SEC regulations.

Comparison to Industry Standards

• The deadlines and procedures outlined in this document are consistent with standard practices for publicly traded companies in the United States.
• Companies like Align Technology and Dentsply Sirona, which operate in the dental and medical device space, also follow similar timelines for their annual meetings and shareholder communications.

Stakeholder Impact

• Shareholders are provided with important dates and deadlines for participation in the annual meeting.
• The announcement ensures that all shareholders have an equal opportunity to submit proposals and nominations.

Next Steps

• The company will file a definitive proxy statement with the SEC.
• Shareholders must submit proposals and nominations by September 27, 2024.
• Shareholders should ensure they are registered by the record date of October 4, 2024 to be eligible to vote.

Key Dates

Keywords

Annual Meeting, Shareholder Proposals, Director Nominations, Proxy Statement, Record Date, Vivos Therapeutics